SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: joemjo who wrote (614)2/14/2000 11:33:00 AM
From: OldAIMGuy  Read Replies (2) of 1154
 
Hi J, If that's so, then if GENE only does collaborative
work, then possibly they will achieve only 1/3 of the
potential valuation of Human Genome. Still, I think that
would be significant.

Item GENE HGSI
Revenues $24MM $23.6MM
Earnings ($0.34) ($0.53)
Price/Book $29.40 $37.35
Price/Sales $30.40 $263.30
Mkt Cap. $739MM $6.70B
Debt/Equity 0.35 0.69

It looks like there's either way too much hot air pumped
into HGSI or there's room for quite a bit more to be pumped
into GENE! :-)

Best regards, Tom
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News